National Hepatitis C prevention strategy; a comprehensive strategy for the prevention and control of hepatitis C virus infection and its consequences
Corporate Authors:National Center for Infectious Diseases (U.S.), Division of Viral Hepatitis.Collection(s):Description:Executive summary -- Hepatitis C virus infection in the United States -- Prevention and control -- Surveillance and research -- Implementation of the National Hepatitis C Prevention Strategy
"On January 22, 1998, the Secretary of the Department of Health and Human Services concurred with the Advisory Committee on Blood Safety and Availability and indicated that persons who may have acquired hepatitis C virus (HCV) infection from blood transfusion be identified through lookback notifications, and that other people at risk for HCV infection also should be identified. The Secretary requested the Centers for Disease Control and Prevention (CDC) to develop a comprehensive plan to address the prevention and control of HCV infection and its consequences. The National Hepatitis C Prevention Strategy is CDC's response to this request, and includes partnerships and coordination with the Agency for Healthcare Research and Quality (AHRQ), Food and Drug Administration (FDA), Health Care Financing Administration (HCFA), Health Resources and Services Administration (HRSA), National Institutes of Health (NIH), Substance Abuse and Mental Health Services Administration (SAMHSA), and other federal, state, and private sector agencies. This CDC strategy serves to protect the public's health by preventing and controlling HCV infection; enhancing health decisions by providing credible information on hepatitis C; and promoting healthy living through strong partnerships with national, State, and local organizations in both the public and private sectors. The goals of the National Hepatitis C Prevention Strategy are to lower the incidence of acute hepatitis C in the United States and reduce the disease burden from chronic HCV infection. Achievement of these goals requires: 1) harm reduction programs directed at persons at increased risk for infection to reduce the incidence of new HCV infections; 2) counseling, testing, and medical evaluation and management of infected persons to control HCV-related chronic liver disease; 3) surveillance to evaluate the effectiveness of prevention activities; and 4) research to provide answers to questions pertinent to the prevention and control of hepatitis C."
Supporting Files:No Additional Files
You may also like: